TITLE

GPhA bullish on generic industry's future

AUTHOR(S)
Cohen, Harold E.
PUB. DATE
May 2001
SOURCE
Drug Topics;5/7/2001, Vol. 145 Issue 9, p64
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Provides information on the Generic Pharmaceutical Association (GPhA), a unification of the generic industry in the United States. Significance of the formation of a united front for the generic industry; Goals of the association; Strategy of pharmacy benefit managers.
ACCESSION #
4436792

 

Related Articles

  • Best may be yet to come for generic drug makers. Kirsche, Michelle L. // Drug Store News;2/14/2005, Vol. 27 Issue 2, p28 

    Reports on the research-and-development pipeline of drug makers in the U.S. Sales of generic companies; Factors contributing to the performance of drug makers; Development of generic pipeline.

  • Is the Generics Industry Ready for Multi-Source Biologics? Challener, Cynthia // Chemical Market Reporter;04/23/2001, Vol. 259 Issue 17, p14 

    Deals with the generic biologic industry. Estimated growth of the biopharmaceutical generics market; Details on the acquisition of Indiana Protein Technologies by Ivax Corp.; European firms preparing to participate in the marketing and sales of generic biopharmaceuticals; Risks faced by a...

  • SEE pharmaceutical market healthy in 2010. Stamov, Valentin; Pavlova, Iskra // SEE Top 100;2011, p46 

    The article focuses on the condition of the pharmaceutical market in 2010 in Southeast Europe (SEE). It notes that sales of pharmaceuticals in the SEE region are influenced by generic drugs. It claims that there is a growth in the pharmaceutical market in Bulgaria in terms of value. It also...

  • Antihypertensives: Generics striking at heart of the market.  // PharmaWatch: Monthly Review;Jan2007, Vol. 6 Issue 1, p13 

    The article focuses on the declining growth rate of the antihypertensive drug market in the U.S. which has been attributed to the penetration of generic drugs. It is cited that the slow growth rate does not manifest a stationary market, but a battle between generic drugs and branded ones....

  • AmerisourceBergen's focus is always on the customer.  // Chain Drug Review;7/16/2012, Vol. 34 Issue 12, p35 

    The article focuses on AmerisourceBergen Corp., which has witnessed development in the areas significant for the future of pharmacy, generic drugs, and the needs of customers and patients. AmerisourceBergen's PRxO Generics Solutions initiative and other programs have been designed to enable...

  • Apotex launches first generic version of Paxil.  // PharmaWatch: CNS;October 2003, Vol. 2 Issue 10, p10 

    Reports on the launch of the first generic version of GlaxoSmithKline's top-selling antidepressant Paxil in the U.S. by Apotex Corp. Challenges faced by Apotex in the development of the generic version of Paxil; Details of the manufacturing process of the generic drug; Capability of the company...

  • THE HATCH-WAXMAN ACT AND MARKET EXCLUSIVITY FOR GENERIC DRUG MANUFACTURERS: AN ENTITLEMENT OR AN INCENTIVE? Mehl, Ashlee B. // Chicago-Kent Law Review;2006, Vol. 81 Issue 2, p649 

    One of Congress' central goals in enacting the Hatch-Waxman Act was to expedite and encourage earlier market entry for generic pharmaceutical products. The Act provides that a generic firm may challenge a drug patent during its term by filing paperwork with the FDA that alleges either that its...

  • Generic Rx Has Majority of Market, IMS Study Shows. Toth, Wendy // SN: Supermarket News;3/17/2008, Vol. 56 Issue 11, p25 

    The article focuses on a study which found that generic prescriptions account for a large part of the pharmaceutical market in the U.S. According to the study, 65 percent of all U.S. prescriptions dispensed are filled with generics. It also noted that as a number of big-name drugs are set to...

  • Foe Turned Friend. Overdorf, Jason; Spring, Silvia // Newsweek (Atlantic Edition);3/5/2007 (Atlantic Edition), Vol. 149 Issue 10, p43 

    The article states that generic drug manufactures in India are teaming up with larger pharmaceutical companies. The Indian pharmaceutical companies previously have been involved in legal battles with the larger pharmaceutical companies for copying their drugs. The partnerships are due in part to...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics